JAK2或CALR突变骨髓增殖性肿瘤疾病起始干细胞的表型特征
研究纳入111例真性红细胞增多症、原发性血小板增多症或原发性骨髓纤维化患者,分析CD34+/CD38-干细胞与CD34+/CD38+祖细胞表型。MPN干细胞表达CD33、CD44、CD47等多种抗原,PMF患者常异常表达CD25、有时CD26;NSGS小鼠证实CD34+/CD38-细胞具疾病起始能力;fedratinib与dBET6可诱导MPN干细胞凋亡并抑制增殖。
要点
- MPN干细胞表达CD33、CD44、CD47、CD52、CD97、CD99、CD105、CD117、CD123、CD133、CD184、CD243和CD274(PD-L1)。
- PMF患者MPN干细胞常异常表达CD25,有时也表达CD26。
- NSGS小鼠中CD34+/CD38- MPN细胞可植入,CD34+/CD38+或CD34-细胞无明显植入。
核心结论
- MPN干细胞呈现独特表型,包括细胞因子受体、免疫检查点分子和其他临床相关靶抗原。
- MPN及sAML肿瘤干细胞表型特征化有助于其富集及开发根除干细胞的治愈性疗法。
研究设计与样本
- 研究纳入111例骨髓增殖性肿瘤患者,包括真性红细胞增多症、原发性血小板增多症或原发性骨髓纤维化。
- 建立推定CD34+/CD38-干细胞和CD34+/CD38+祖细胞的表型,并在NSGS小鼠中验证疾病起始能力。
主要发现
- 在几乎所有受检患者中,CD34+/CD38-干细胞表达CD33、CD44、CD47、CD52、CD97、CD99、CD105、CD117、CD123、CD133、CD184、CD243和CD274(PD-L1)。
- PMF患者MPN干细胞常表达CD25,有时也异常表达CD26。
- MPN干细胞未大量表达CD90、CD273(PD-L2)、CD279(PD-1)、CD366(TIM-3)、CD371(CLL-1)或IL-1RAP。
- 向sAML进展过程中CD34+/CD38-干细胞表型未发生显著变化。
- NSGS小鼠中CD34+/CD38- MPN细胞可植入,CD34+/CD38+或CD34-细胞未产生明显植入。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloproliferative neoplasms (MPN) are characterized by uncontrolled expansion of myeloid cells, disease-related mutations in certain driver-genes including JAK2, CALR, and MPL, and a substantial risk to progress to secondary acute myeloid leukemia (sAML). Although behaving as stem cell neoplasms, little is known about disease-initiating stem cells in MPN. We established the phenotype of putative CD34+ /CD38- stem cells and CD34+ /CD38+ progenitor cells in MPN. A total of 111 patients with MPN suffering from polycythemia vera, essential thrombocythemia, or primary myelofibrosis (PMF) were examined. In almost all patients tested, CD34+ /CD38- stem cells expressed CD33, CD44, CD47, CD52, CD97, CD99, CD105, CD117, CD123, CD133, CD184, CD243, and CD274 (PD-L1). In patients with PMF, MPN stem cells often expressed CD25 and sometimes also CD26 in an aberrant manner. MPN stem cells did not exhibit substantial amounts of CD90, CD273 (PD-L2), CD279 (PD-1), CD366 (TIM-3), CD371 (CLL-1), or IL-1RAP. The phenotype of CD34+ /CD38- stem cells did not change profoundly during progression to sAML. The disease-initiating capacity of putative MPN stem cells was confirmed in NSGS mice. Whereas CD34+ /CD38- MPN cells engrafted in NSGS mice, no substantial engraftment was produced by CD34+ /CD38+ or CD34- cells. The JAK2-targeting drug fedratinib and the BRD4 degrader dBET6 induced apoptosis and suppressed proliferation in MPN stem cells. Together, MPN stem cells display a unique phenotype, including cytokine receptors, immune checkpoint molecules, and other clinically relevant target antigens. Phenotypic characterization of neoplastic stem cells in MPN and sAML should facilitate their enrichment and the development of stem cell-eradicating (curative) therapies.
引用
- Ivanov D, Milosevic Feenstra JD, Sadovnik I, et al. Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms. Am J Hematol. 2023. PMID: 36814396. doi:10.1002/ajh.26889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。